Sugi Predict

Sugi Predict / Compounds / SCHEMBL825537

SCHEMBL825537

SCHEMBL825537

O=C(Cl)OC(Cl)c1ccccc1

nearest known ligand 0.48

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ CYP2D6 P10635 1/20 0.48
▸ KMT2A Q03164 2/20 0.45
▸ SRC P12931 1/20 0.43
▸ TSHR P16473 2/20 0.42
▸ LMNA P02545 3/20 0.41
▸ MAPK1 P28482 1/20 0.41
▸ ALDH1A1 P00352 2/20 0.41
▸ TP53 P04637 1/20 0.41
▸ CES2 O00748 1/20 0.40
▸ CES1 P23141 1/20 0.40
▸ MEN1 O00255 1/20 0.40
▸ CYP3A4 P08684 1/20 0.39
▸ HPGD P15428 1/20 0.39
▸ ESR1 P03372 1/20 0.39
▸ ESR2 Q92731 1/20 0.39
▸ TDP1 Q9NUW8 1/20 0.39
▸ L3MBTL1 Q9Y468 1/20 0.39
▸ HCAR2 Q8TDS4 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL984298 0.84 CYP2D6 (0.44) CYP2D6KMT2ASRCTSHRLMNA
SCHEMBL27840777 0.84 CYP2D6 (0.44) CYP2D6KMT2ASRCTSHRLMNA
SCHEMBL1096587 0.84 CYP2D6 (0.44) CYP2D6KMT2ASRCTSHRLMNA
SCHEMBL9815844 0.81 ESR1 (0.42) CYP2D6KMT2ASRCTSHRLMNA
SCHEMBL286761 0.81 CYP2D6 (0.48) CYP2D6KMT2ASRCTSHRLMNA
SCHEMBL1408551 0.81 ALDH1A1 (0.55) CYP2D6KMT2ASRCTSHRLMNA
SCHEMBL3292508 0.80 ESR1 (0.53) CYP2D6KMT2ASRCTSHRLMNA
SCHEMBL661908 0.79 CYP2D6 (0.40) CYP2D6KMT2ASRCTSHRLMNA
SCHEMBL28435260 0.79 CYP2D6 (0.40) CYP2D6KMT2ASRCTSHRLMNA
SCHEMBL9860565 0.79 HCAR2 (0.56) CYP2D6KMT2ASRCTSHRLMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 53 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4705289-A1 PRODRUGS OF XANOMELINE, PRODRUGS OF TROSPIUM AND METHODS OF USE THEREOF Terran Biosciences Inc. (US) 2026-03-11 — — EP disclosed
WO-2024226691-A1 PRODRUGS OF XANOMELINE, PRODRUGS OF TROSPIUM AND METHODS OF USE THEREOF TERRAN BIOSCIENCES INC. (US) 2024-10-31 — — WO disclosed
US-20240287108-A1 nSMASE2 INHIBITOR PRODRUGS WITH ENHANCED ORAL AND BRAIN EXPOSURES THE JOHNS HOPKINS UNIVERSITY 2024-08-29 — — US disclosed
US-11926640-B2 Prodrugs of glutamine analogs THE JOHNS HOPKINS UNIVERSITY (US) 2024-03-12 — — US disclosed
EP-3328827-B1 PRODRUGS OF GLUTAMINE ANALOGS UNIV JOHNS HOPKINS (US) 2023-07-05 — — EP disclosed
WO-2022261120-A1 nSMASE2 INHIBITOR PRODRUGS WITH ENHANCED ORAL AND BRAIN EXPOSURES THE JOHNS HOPKINS UNIVERSITY (US) 2022-12-15 — — WO disclosed
US-20220106595-A1 ANTIBACTERIAL ANTISENSE AGENTS Pedanius Therapeutics Limited (GB) 2022-04-07 — — US disclosed
US-20210206787-A1 PRODRUGS OF GLUTAMINE ANALOGS Ústav organické chemie a biochemie AV CR, v.v.i. (CZ) 2021-07-08 — — US disclosed
US-10954257-B2 Prodrugs of glutamine analogs THE JOHNS HOPKINS UNIVERSITY (US) 2021-03-23 — — US disclosed
US-10738066-B2 Prodrugs of glutamine analogs THE JOHNS HOPKINS UNIVERSITY (US) 2020-08-11 — — US disclosed
WO-2000061542-A1 CASPASE INHIBITORS AND THE USE THEREOF CYTOVIA, INC. (US) 2000-10-19 — — WO disclosed
US-5843973-A Thiazolidinone compounds and composition for angina pectoris comprising the compounds as an active ingredient SANKYO COMPANY, LIMITED (JP) 1998-12-01 — — US disclosed
EP-0798298-A1 THIAZOLIDINONE COMPOUNDS OR ANGINA PECTORIS REMEDY OR PREVENTIVE CONTAINING THE SAME AS ACTIVE INGREDIENT SANKYO COMPANY LIMITED (JP) 1997-10-01 — — EP disclosed
US-5510531-A ANTIINFLAMMATROY AGENTS, MUSCULAR DISORDERS SUNTORY LIMITED (JP) 1996-04-23 — — US disclosed
US-5081284-A N-Oxomethyl-Substituted Peptide SUNTORY LIMITED (JP) 1992-01-14 — — US disclosed
US-4614829-A REACTING ALDEHYDES WITH TRICHLORMETHYL CHLOROFORMATE OR DI-TRICHLOROMETHYLCARBONATE SOCIETE NATIONALE DES POUDRES ET EXPLOSIFS (FR) 1986-09-30 — — US disclosed
US-4592874-A CATALYTIC REACTION OF PHOSGENE AND ALDEHYDE SOCIETE NATIONALE DES POUDRES ET EXPLOSIFS (FR) 1986-06-03 — — US disclosed
US-4592872-A Reacting phosgene with an aldehyde in presence of a catalyst SOCIETE NATIONALE DES POUDRES ET EXPLOSIFS (FR) 1986-06-03 — — US disclosed
US-4358606-A Esters of phenalkyloxycarbonylamino acids ZOECON CORPORATION (US) 1982-11-09 — — US disclosed
US-3991199-A ANALGESICS AND SEDATIVES ENDO LABORATORIES, INC. (US) 1976-11-09 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210206787-A1 PRODRUGS OF GLUTAMINE ANALOGS GLUL, GLS, GLS2 CYP2D6 104/4885KMT2A 1913/4885SRC 2693/4885
US-10738066-B2 Prodrugs of glutamine analogs GLUL, GLS, GLS2 CYP2D6 68/4885KMT2A 2112/4885SRC 2408/4885
US-20240287108-A1 nSMASE2 INHIBITOR PRODRUGS WITH ENHANCED ORAL AND BRAIN EXPOSURES SGMS2, SMPD2, CERS2 CYP2D6 1605/4885KMT2A 469/4885SRC 2765/4885
US-11926640-B2 Prodrugs of glutamine analogs GLUL, GLS, GLS2 CYP2D6 68/4885KMT2A 2112/4885SRC 2408/4885
US-20220106595-A1 ANTIBACTERIAL ANTISENSE AGENTS SLC47A1, SLC47A2, ZFR CYP2D6 4241/4885KMT2A 2858/4885SRC 4804/4885
US-10954257-B2 Prodrugs of glutamine analogs GLUL, GLS, GLS2 CYP2D6 68/4885KMT2A 2112/4885SRC 2408/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.